Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

1,630 public trials 214 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

NCT00060684

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +20 more
Locations
  • Arizona Clinical Research Center Tucson, Arizona, United States
  • Greater Baltimore Medical Center Baltimore, Maryland, United States
  • New Mexico Onc/Hem Consultants, Inc. Albuquerque, New Mexico, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

NCT00274742

Conditions
Bites and Stings, Chemically-Induced Disorders, Disease Attributes, +15 more
Locations
  • Medizinische Klinik 5, Hämatologie & Internistische Onkologie, Universitätsklinikum Erlangen Erlangen, Germany
  • Universitätsklinikum Essen, Klinik für Hämatologie, Medizinische Klinik und Poliklinik Essen, Germany
  • Universtätsklinkum Tübingen Tübingen, Germany
  • Universitätsklinikum Ulm, Abteilung Innere Medizin III Ulm, Germany
View Trial Details
Completed

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

NCT00435916

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic-Arizona Scottsdale, Arizona, United States
  • University of California Los Angeles Los Angeles, California, United States
  • Stanford University Medical Center Palo Alto, California, United States
View all 14 locations
View Trial Details
Completed

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

NCT00082784

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, +33 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States
  • University of Pittsburgh Pittsburgh, Pennsylvania, United States
  • Medical University of South Carolina Charleston, South Carolina, United States
View Trial Details
Completed

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

NCT01026415

Conditions
Carcinoma, Carcinomas, Disease, Hodgkin, +14 more
Locations
  • City of Hope Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • St. Francis Medical Group Oncology & Hematology Specialists Indianapolis, Indiana, United States
  • Karmanos Cancer Institute / Wayne State University Detroit, Michigan, United States
View Trial Details
Completed

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

NCT00655837

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • University of Colorado Aurora, Colorado, United States
  • Oncology Specialists Park Ridge, Illinois, United States
View Trial Details
Completed

A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

NCT01015911

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +20 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • UCLA Medical Center / University of California at Los Angeles Los Angeles, California, United States
  • Karmanos Cancer Institute / Wayne State University Detroit, Michigan, United States
View Trial Details
Completed

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

NCT00430846

Conditions
Disease, Hodgkin, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Washington University St Louis, Missouri, United States
  • Weill Cornell Medical College New York, United States
  • University of Texas/MD Anderson Cancer Center Houston, Texas, United States
View Trial Details

Related conditions